Safer, more expensive iodinated contrast agents: how do we decide?
The advantages of the new, safer, but more expensive iodinated contrast agents are discussed, and opinions on which patient groups should receive the agents are presented.
D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D003365:Costs and Cost Analysis; D006801:Humans; D007472:Iohexol; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D011859:Radiography / Q000191:economics; D012306:Risk; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; D007472:Iohexol; D007479:Iopamidol; D008793:Metrizamide